How to Corticotropin releasing factor?

Activatable clostridial toxins,High purity peptides,Urocortin-III and uses thereof,Stresscopins and their uses,Corticotropin releasing factor 2 receptor agonists

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

42results about "Corticotropin releasing factor" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Activatable clostridial toxins

InactiveUS20090018081A1Long duration of therapyOvercome resistanceHydrolasesPeptide/protein ingredientsClostridial toxinNucleic acid

Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.

View all

Owner:ALLERGAN INC

High purity peptides

InactiveUS20080287650A1High HPLC purityThymosin peptidesPeptide preparation methodsNesiritideHPLC measurement

The invention relates to methods for the preparation of highly purified peptides. The peptides are prepared in high optical purity of at least about 98.5%, and preferably at least about 99%. Specifically, Nesiritide (SEQ. ID NO. 1) having a purity of at least 99% as measured by HPLC and containing about 0.05% to about 0.5% [D-His]-Nesiritide (SEQ. ID NO. 1) as measured by chiral GC / MS.

Owner:TEVA PHARM USA INC

Urocortin-III and uses thereof

InactiveUS6953838B2Nervous disorderPeptide/protein ingredientsHigh homologyHuman genome database

A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2α or β. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.

View all

Owner:RES DEVMENT FOUND

Stresscopins and their uses

InactiveUS7291341B2Suppress food intakeSuppress heat-induced edemaCompound screeningNervous disorderHypotensive agentsHeat induced

The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.

View all

Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Corticotropin releasing factor 2 receptor agonists

InactiveUS6936585B2Effective treatmentPeptide/protein ingredientsMuscular disorderDiseaseCorticotropins

Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.

Owner:APTALIS PHARMA

Melanocortin receptor antagonists and modulations of melanocortin receptor activity

InactiveUS6953779B2Improve effectivenessPeptide/protein ingredientsDepsipeptidesMelanomaMCR-1

The clinical outcome of disseminated melanoma is grim. Small molecular weight antagonists (preferably about seven amino acid residues) specific for MCR on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clinical significance. A particularly preferred antagonist is p-anisoyl-[D-Arg6,9, D-Lys11, D-Leu12] dynorphin A(6-12)-NH2, which is an excellent antagonist of the MCR-1 receptor.

Melanocortin receptor antagonists and modulations of melanocortin receptor activity

View all

Owner:RGT UNIV OF CALIFORNIA

Corticotropin releasing factor 2 receptor agonists

InactiveUS7192923B2Cell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsMuscular dystrophyAdrenal gland

Owner:APTALIS PHARMA

CRFR1 selective ligands

InactiveUS20040204564A1Easy to carryHigh throughput screeningNervous disorderPeptide/protein ingredientsStereochemistryPeptide analog

CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. These analogs exhibit CRF agonist activity.

Owner:SALK INST FOR BIOLOGICAL STUDIES

Amino diacids containing peptide modifiers

InactiveUS20160207957A1Carbamic acid derivatives preparationPeptide/protein ingredientsCombinatorial chemistryPerylene derivatives

The present invention relates to peptide modifier compounds of Formula (1), or a salt thereof, wherein: a is an integer from 1 to 10, more preferably from 1 to 3; b is an integer from 0 to 7; Z is a terminal group and Y is a bivalent group. Further aspects of the invention relate to intermediates in the preparation of compounds of Formula (1), and the use of compounds of Formula 1 in the synthesis of peptide derivatives.

Amino diacids containing peptide modifiers

View all

Owner:CHEM & BIOPHARML LAB OF PATRAS

Corticotropin-releasing hormone analogs

InactiveUS6849600B2CorticotropinPeptide preparation methodsCorticotropin-releasing hormoneAmino acid

This invention relates to peptide analogs of corticotropin-releasing hormone. Particularly, the invention provides analogs wherein the 38th amino acid from the N-terminus is D-Nle, i.e. [D-Nle38]-CRH peptide.

Owner:RGT UNIV OF CALIFORNIA

CRH and POMC effects on animal growth

ActiveUS20050221332A1Increase probabilityMicrobiological testing/measurementFermentationCarcass weightPredictive value

The present invention provides for selection of bovine animals that will display phenotypes associated with increased rates of growth. These phenotypes include hot carcass weight, average daily gain, shipping weight, end of test rib eye area, and adjusted weaning weight which is a measure of post-natal growth, based on the knowledge of their CRH, POMC and MC4R genotypes. The predictive value comes from the discovery that certain single nucleotide polymorphisms (SNPs) in these genes are linked to higher growth rate phenotypes. Specifically, the phenotypes that correlated with specific SNP's are end-of-test rib-eye area, adjusted weaning weight, average daily gain, shipping weight and hot carcass weight. The invention also provides novel kits that can be used in making the determination of these genotypes. The invention further provides for methods of screening bovines to predict which animals will have higher growth rate, allowing producers to selectively breed and manage animals based on desired characteristics, thereby maximizing productivity and profitability in commercial meat production operations.

View all

Owner:UNIVERSITY OF SASKATCHEWAN

CRFR1 selective ligands

InactiveUS7498300B2Nervous disorderCell receptors/surface-antigens/surface-determinantsSolid-phase synthesisStereochemistry

CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. These analogs exhibit CRF agonist activity. One exemplary analog that may be made by solid-phase synthesis is (cyclo 31-34)[Ac-Pro4, D-Phe12, Nle21,38, Glu31, Lys34]-r / hCRF(4-41).

View all

Owner:SALK INST FOR BIOLOGICAL STUDIES

Methods for the expression of peptides and proteins

ActiveUS20160138066A1Inhibitory activityInefficient transportAntibody mimetics/scaffoldsPhosphorus-oxygen lyasesRecombinant peptideADAMTS Proteins

The present invention lies in the field of molecular biology, recombinant peptide and protein expression and relates to methods comprising nucleic acid sequences comprising allocrites of T1SSs or fragments thereof for the efficient production of recombinant Pe OIs and Pr OI. The allocrites or fragments thereof improve the expression of PeOI and Pr OI as IB and function as IB-tags.

Methods for the expression of peptides and proteins

View all

Owner:NUMAFERM GMBH

Chimera Compositions and Methods of Use

InactiveUS20110027909A1Enhanced signalAccelerated identification and developmentSugar derivativesPeptide/protein ingredientsOrganismal ProcessChimera Protein

This invention is directed to novel compositions, process methods, research tools, and use of these in the identification and development of novel therapeutic and / or diagnostic products. The compositions of the invention are chimera proteins that in essence recreate and / or potentiate one or more protein complex interactions that occur in vivo in the modulation of biological processes.

View all

Owner:RGT UNIV OF CALIFORNIA

CRF conjugates with extended half-lives

InactiveUS20100249027A1Effective treatmentReduce dosing frequencyOrganic active ingredientsPeptide/protein ingredientsHalf-lifeDose sparing

The present invention relates to conjugates of CRF that have been modified to include a moiety that protects CRF from degradation and prolongs the half-life of CRF. The CRF conjugates of the invention have an increased half-life which results in a dose-sparing effect and less frequent administration

View all

Owner:HENRY WILLIAM

Promoter sequences for urocortin II and the use thereof

InactiveUS7087385B2Avoid serious problemsAvoid side effectsSugar derivativesHydrolasesCell biologyNucleic acid

Various human urocortin II promoter sequences are disclosed. Nucleic acids and host cells that contain the promoter sequences are also disclosed. Further disclosed are various methods involving the use of these sequences. Also disclosed are methods of modulating the activity of a human urocortin II promoter sequence and methods of modulating urocortin II expression in a cell.

Promoter sequences for urocortin II and the use thereof

View all

Owner:WISCONSIN ALUMNI RES FOUND

Methods for the expression of peptides and proteins

ActiveUS10443081B2Antibody mimetics/scaffoldsPhosphorus-oxygen lyasesRecombinant peptideADAMTS Proteins

View all

Owner:NUMAFERM GMBH

Local pain-combating agent

InactiveUS20040138115A1Reduce inhibitionHigh transfection efficiencyPeptide/protein ingredientsAntibody mimetics/scaffoldsTace inhibitorMedicine

A remedy to suppress the sensation of pain, especially in chronic inflammatory diseases, by means of expressing endogenous neuroendocrine peptides at the site of inflammation. In particular, the invention relates to the expression of POMC or CRF from locally injected DNA expression constructs, preferably covalently peptide-modified expression constructs.

View all

Owner:MOLOGEN AG

Crfr1 selective ligands

InactiveUS20090149629A1Nervous disorderCell receptors/surface-antigens/surface-determinantsUrotensinsSolid-phase synthesis

CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. Some of these analogs exhibit CRF agonist activity. One exemplary analog that may be made by solid-phase synthesis is:(cyclo 31-34)[Ac-Pro4, D-Phe12, Nle18,21, Glu31, Lys34]-sucker urotensin(4-41).

View all

Owner:SALK INST FOR BIOLOGICAL STUDIES

Dietary peptides

InactiveCN108473535APeptide/protein ingredientsMetabolism disorderVascular diseaseDiabetes mellitus

The present invention relates to novel peptides, composition comprising such peptides including nutritional supplements and methods for inducing satiation and satiety, for weight management and preventing or reducing the incidence of obesity, or for preventing or reducing cardiovascular diseases, atherosclerosis, hypertension, hepatosteatosis, cancer and / or diabetes.

View all

Owner:EATING & LIVING PTE LTD

Urocortin-III and uses thereof

InactiveUS20060003937A1Nervous disorderPeptide/protein ingredientsHigh homologyGenomic DNA

View all

Owner:RES DEVMENT FOUND

Medicament for preventing or treating heart failure

ActiveUS20190160151A1Good treatment effectEffective treatmentOrganic active ingredientsPeptide-nucleic acidsBULK ACTIVE INGREDIENTCorticotropin releasing hormone receptor 2

A medicament for preventing or treating heart failure containing an antagonist of the corticotropin releasing hormone receptor 2 as an active ingredient.

View all

Owner:RAQUALIA PHARMA INC

Dietary peptides

PendingUS20220248736A1Peptide/protein ingredientsMetabolism disorderDiabetes mellitusNutrition supplementation

View all

Owner:DIET4LIFE APS

Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes

PendingUS20210024603A1Peptide/protein ingredientsAntibody mimetics/scaffoldsUrocortinCellular antigens

Despite the notion that human CD8+ T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naive CD8+ T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.

Owner:UNIVERSITÉ PARIS CITÉ +3